Targeting GM-CSF in rheumatoid arthritis

Avci A. B., Feist E., Burmester G. R.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.34, sa.4, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 4
  • Basım Tarihi: 2016
  • Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: rheumatoid arthritis, GM-CSF, mavrilimumab, MOR103, namilumab, COLONY-STIMULATING FACTOR, COLLAGEN-INDUCED ARTHRITIS, HUMAN MONOCLONAL-ANTIBODY, FACTOR-DEFICIENT MICE, SYNOVIAL TISSUE, MACROPHAGE POLARIZATION, FELTYS-SYNDROME, EFFECTOR PHASE, BETA-SUBUNIT, DOUBLE-BLIND
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is well-known as a haemopoietic growth factor. However, it is also essential in regulating functions of mature myeloid cells such as macrophages. Preclinical studies and observations of flares of arthritis in patients following GM-CSF treatment supported its important contribution to the pathogenesis of rheumatoid arthritis (RA). As the most advanced compound, mavrilimumab, a monoclonal antibody against GM-CSF receptor, has already completed phase II trials with a long term of follow-up period of 74 weeks. During this exposure period, an acceptable sustained safety and tolerability profile has been observed addressing the concerns of development of cytopenias or pulmonary alveolar proteinosis. Of note, a rapid and sustained efficacy and normalisation of acute phase reactants were consistently shown in studies both targeting GM-CSF and its receptor. Its tumour necrosis factor (TNF) independent mode of action with concurrent blockade of GM-CSF as well as IL-17 signalling reported from preclinical studies supports the assumption that it can be a useful biologic and an alternative agent in TNF inhibitor resistant patients with RA. Therefore, subsequent studies are warranted to investigate the safety and efficacy of GM-CSF blocking agents in different subgroups of RA.